Joseph M Rey,* Michael J Dudley†
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14 857 suicides. Acta Psychiatr Scand 2005; 111: 286-290.<eMJA full text>
- 2. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385-388.
- 3. Treatment for Adolescents with Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA 2004; 292: 807-820.
- 4. Beautrais A. Risk factors for suicide and attempted suicide among young people. Aust N Z J Psychiatry 2000; 34: 420-436.
- 5. Royal Australian and New Zealand College of Psychiatrists, Royal Australian College of General Practitioners and Royal Australasian College of Physicians. Clinical guidance on the use of antidepressant medications in children and adolescents. Available at: http://www.ranzcp.org/publicarea/pracguid.asp (accessed Jun 2005).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Joseph Rey was a member of the advisory committee for Strattera (Eli Lilly) and Concerta (Janssen-Cilag) and was funded by Eli Lilly to attend an international conference. Michael Dudley attends Pfizer-sponsored peer review dinners, and has (before the recent debates about drug company gifts) received bags, pens, and a CD.